Biotechnology Daily
more-
Third Harmonic, latest victim of raised liver enzymes, shutters trial and sees shares slide
The curse of raised liver enzymes has struck again, with Third Harmonic the latest company…
Sio confirms gene therapy company will be liquidated after tough year
AstraZeneca’s Alexion hopes to extend dominance in PNH as Big Pharma competitors close in
Takeda’s Poseida partnership starts to pay off with promising hemophilia A gene therapy data
Avidity pushes phase 1/2 data as proof of first targeted RNA into muscle, but FDA partial hold remains
Market Watch
more-
Lam Research to trim 7% of workforce, increase R&D spending as memory-chip crunch hits outlook
Chipmaking equipment company is latest Silicon Valley company to announce cuts
Bio Business News
more
Axonics nabs Canadian nod for 20-year incontinence implant requiring fewer recharges
Hot on the heels of the U.S. launch of its…
Gates, Bezos back $75M round for Synchron’s drill-free brain-computer interface implant
After announcing that it had implanted its brain-computer interface in…
45 days later, BioCryst abandons another program, citing stiff competition
Last month, BioCryst trimmed down its pipeline to two drugs…
World News
more
Stocks close with a round of records, Dow clinches 35,000
U.S. stocks swept to another round of records Monday as…
Equifax stock surges toward biggest gain in 12 years after ‘impressive’ business update
Shares of Equifax Inc. EFX, +7.84% shot up 9.3% into…
SpaceX Starlink wins permit to send internet to customers like you
SpaceX has been busy building its Starlink satellite constellation. To…
Third Harmonic, latest victim of raised liver enzymes, shutters trial and sees shares slide
Sio confirms gene therapy company will be liquidated after tough year
AstraZeneca’s Alexion hopes to extend dominance in PNH as Big Pharma competitors close in
Takeda’s Poseida partnership starts to pay off with promising hemophilia A gene therapy data
Axonics nabs Canadian nod for 20-year incontinence implant requiring fewer recharges
Gates, Bezos back $75M round for Synchron’s drill-free brain-computer interface implant
45 days later, BioCryst abandons another program, citing stiff competition
Innovent plucks Chinese rights to LG Chem’s gout disease treatment in nearly $100M deal
Lam Research to trim 7% of workforce, increase R&D spending as memory-chip crunch hits outlook
U.S. economy doesn’t look as good as GDP suggests